evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract
4819,GENE_BACKGROUND,,"The BTK (Bruton’s agammaglobulinemia tyrosine kinase) gene encodes a cytoplasmic tyrosine kinase particularly important in B-lymphocyte biology. Loss of function mutations in BTK lead to B-cell deficiencies and immunodeficiency known as X-linked agammaglobulinemia (XLA) (PMID: 8380905). Patients with XLA fail to produce sufficient immunoglobulin and have a deficient humoral immune response. BTK is activated by the B-cell Receptor (BCR) when BCR associated tyrosine kinases (such as SYK and LYN) phosphorylates BTK at the plasma membrane at residue Y551 (PMID: 8629002). The major target of BTK phosphorylation is phospholipase C-γ2 (PLCγ2). Activation of PLCγ2 by BTK results in Ca++ influx and activation of the NFAT, NFkB and MAPK pathways (PMID: 8691147, 10811867). BTK signaling is also implicated in chemokine receptor signaling in lymphocyte trafficking and in Toll-like receptor signaling in the immune response (PMID: 17239630, 23967355). BTK signaling is critical for growth of B-cell derived malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and waldenstrom's macroglobulinemia (WM) (PMID: 24658273). BTK can be over-expressed in B-cell malignancies (PMID: 21422473, 23962569). In AML cells, BTK was shown to be involved in signaling from FLT3-ITD and TLR9 receptors that were important for cell survival and proliferation (PMID: 25605370). BTK inhibition has been a successful means of therapy in hematologic malignancies. However, acquired resistance has been observed through mutations in BTK itself and in downstream effectors such as PLCG2 (PMID: 24869598), while primary refractory disease has been observed in alternative signaling pathways that activate the same target pathways, such as specific mutations in CXCR4 (PMID: 24912431) and MYD88 (Abstract: Wilson et al. Abstract# 686, ASH 2012. http://www.bloodjournal.org/content/120/21/686?sso-checked=true).",,2017-03-01,,695,BTK,Bruton tyrosine kinase,True,ENST00000308731,NM_000061.2,AT,IMD1,AGMX1,ATK,BPK,XLA,PSCTK1,False,21422473,Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.,Blood,2018-06-09T20:11:00,117,23,6287-96,Herman SE et al,doi: 10.1182/blood-2011-01-328484,,0001-06-09,,24869598,Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.,The New England journal of medicine,2018-06-12T20:14:00,370,24,2286-94,Woyach JA et al,doi: 10.1056/NEJMoa1400029,,0001-06-12,,23962569,Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.,Leukemia research,2018-10-01T20:13:00,37,10,1271-7,Cinar M et al,doi: 10.1016/j.leukres.2013.07.028,,0001-10-01,,,,,,,,,,,http://www.bloodjournal.org/content/120/21/686?sso-checked=true,null. null. .,"Wilson et al. Abstract# 686, ASH 2012",17239630,Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.,Immunity,2018-01-01T20:07:00,26,True,93-104,de Gorter DJ et al,,,2018-01-01T01:04:00,,8629002,Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.,"Science (New York, N.Y.)",0001-02-09,271,5250,822-5,Rawlings DJ et al,,,0001-02-09,,23967355,Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin.,PloS one,2013,8,8,e74103,Kenny EF et al,doi: 10.1371/journal.pone.0074103,,Kenny EF et al. PloS one. 2013;8(8)e74103.,,25605370,FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.,Blood,2018-03-19T20:15:00,125,12,1936-47,Oellerich T et al,doi: 10.1182/blood-2014-06-585216,,0001-03-19,,24912431,"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",Leukemia,2018-01-01T20:15:00,29,True,169-76,Cao Y et al,doi: 10.1038/leu.2014.187,,0001-01-01,,24658273,Targeting Bruton's tyrosine kinase in B cell malignancies.,Nature reviews. Cancer,2018-04-01T20:14:00,14,4,219-32,Hendriks RW et al,doi: 10.1038/nrc3702,,0001-04-01,,10811867,Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.,The Journal of experimental medicine,2018-05-15T20:00:00,191,10,1745-54,Petro JB et al,,,0001-05-15,,8380905,The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.,Nature,0001-01-21,361,6409,226-33,Vetrie D et al,,,0001-01-21,,8691147,A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.,The Journal of experimental medicine,0001-07-01,184,True,31-40,Takata M et al,,,0001-07-01,
4818,GENE_SUMMARY,,"BTK, an intracellular kinase, is overexpressed in B-cell malignancies.",,2017-10-23,,695,BTK,Bruton tyrosine kinase,True,ENST00000308731,NM_000061.2,AT,IMD1,AGMX1,ATK,BPK,XLA,PSCTK1,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
